Does Retatrutide Cause Infertility? What the Evidence Actually Supports

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• Retatrutide is investigational. FormBlends does not sell or supply it. This article is educational.
• No published human evidence supports a claim that retatrutide causes infertility in either sex.
• The dominant observed effect in the GLP-1 class is the opposite: weight-loss-mediated improvement in markers associated with fertility.
• Animal data show signals at maternally toxic doses, which produces pregnancy-avoidance labeling, not fertility-impairment labeling.
• The half-life of approximately 6 days drives a roughly 4-5 week washout estimate for full pharmacologic clearance.

Direct answer

No published human evidence supports the claim that retatrutide causes infertility. Direct human fertility data for retatrutide has not been reported. Class-wide GLP-1 receptor agonist data suggests the opposite pattern in people with obesity: weight loss restores ovulation in women with obesity-related anovulation and improves testosterone and sperm parameters in men with obesity-related hypogonadism. Pregnancy-avoidance labeling for approved GLP-1 drugs reflects fetal-exposure concerns from animal data, not human fertility impairment.

Table of contents

1. The conflation that drives the question
2. What "infertility" means clinically vs colloquially
3. What the Phase 2 trial reported
4. Class-wide evidence in women
5. Class-wide evidence in men
6. Animal data: what it actually shows
7. The pharmacokinetic washout question
8. Pregnancy avoidance vs fertility impairment
9. Contrary view: what the data cannot rule out
10. Decision framework
11. FAQ
12. Sources

The conflation that drives the question

Three things get bundled into the word "infertility" in online discussion of GLP-1 medications:

First, pregnancy-avoidance labeling. Approved GLP-1 drugs carry labeling recommending discontinuation before planned pregnancy due to animal data suggesting fetal effects. This is about exposing a developing pregnancy to the drug, not about preventing conception.

Second, weight-loss-mediated menstrual changes. Some women experience cycle changes during rapid weight loss, including transient amenorrhea or oligomenorrhea. These are weight-loss effects, not direct drug effects on the reproductive axis.

Third, the long washout period. The 6-day half-life of retatrutide and similar drugs means full clearance takes weeks. This timing question can read as a fertility issue when it is actually a drug-clearance issue.

None of these support a claim that the drug causes infertility.

What "infertility" means clinically vs colloquially

Clinical infertility is defined as failure to conceive after 12 months of unprotected intercourse (or 6 months in women over 35). It is a population-level definition that captures a wide range of underlying causes, from anovulation to tubal disease to oligospermia.

Colloquial use of "infertility" often refers to anything that makes conception harder, including circumstantial factors like medication washout periods or temporary cycle disruption. The two usages produce very different conclusions about a drug's effects.

For retatrutide, the relevant question is whether any direct effect on reproductive physiology has been demonstrated. The answer in published literature is no.

What the Phase 2 trial reported

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported safety endpoints including gastrointestinal adverse events, hepatic enzyme changes, heart rate, and skin events. Reproductive outcomes were not pre-specified endpoints. There is no published infertility signal, no reported menstrual cycle changes, and no fertility marker data.

The TRIUMPH Phase 3 program is similarly structured around weight loss, cardiometabolic markers, and safety. Reproductive endpoints are not a primary focus.

Absence of a reported signal does not equal absence of a signal. It does mean that no signal has emerged in the trial program that would justify a claim of drug-induced infertility.

Class-wide evidence in women

In women using approved GLP-1 medications for obesity:

• Reports of "Ozempic babies" reflect restoration of ovulation in women with previously anovulatory cycles, particularly in PCOS and obesity-related anovulation.
• Several small randomized trials of liraglutide and semaglutide in PCOS report improvement in menstrual regularity alongside weight loss.
• No published study has reported a class-wide signal of impaired conception in women using GLP-1 medications.

The pattern: weight loss often increases fertility in this population, sometimes to the point that contraception failure becomes the relevant clinical issue.

Class-wide evidence in men

In men using approved GLP-1 medications for obesity:

• Testosterone tends to rise in men with obesity-related hypogonadism, often returning toward normal.
• SHBG rises, normalizing free testosterone calculations.
• Sperm parameters improve in studies of weight loss generally, with smaller GLP-1-specific datasets suggesting similar patterns.
• Erectile function improves alongside weight loss in studies that have measured it.

Again, the pattern is improvement rather than impairment. No class-wide signal of drug-induced male infertility has emerged.

Animal data: what it actually shows

Preclinical reproductive toxicology programs for GLP-1 receptor agonists include male and female fertility studies (typically segment I), embryo-fetal development studies (segment II), and pre- and post-natal development studies (segment III). The standard findings across the class:

• Male fertility studies have generally been unremarkable at clinically relevant exposures.
• Female fertility studies have not shown significant impairment of ovulation, mating, or conception at relevant exposures.
• Embryo-fetal development studies have shown effects on offspring (reduced fetal weight, structural variations) at exposures that produce maternal toxicity (reduced food intake, weight loss).
• Effects diminish at lower, more clinically representative exposures.

The pattern that drives pregnancy-avoidance labeling is fetal exposure at the time of organogenesis, not infertility. Eli Lilly has not published the full retatrutide preclinical reproductive package, but class-wide patterns are the most reasonable extrapolation.

The pharmacokinetic washout question

Retatrutide has a half-life of approximately 6 days based on Phase 2 PK data. Five to six half-lives is the conventional benchmark for "complete" clearance (about 98-99 percent), translating to roughly 4-5 weeks after the last dose.

The two-month pre-pregnancy discontinuation guideline for approved GLP-1 drugs reflects this PK plus a buffer for biological variability. It is intended to ensure the drug has cleared by the time conception attempts begin, not to allow recovery from a fertility-impairing effect.

This is an important distinction. A drug with a long washout for pregnancy planning is not the same as a drug that impairs fertility. The washout is about pre-pregnancy clearance; fertility during the on-drug period is largely unaffected in the available data.

Pregnancy avoidance vs fertility impairment

The two concepts often get confused. The differences:

Concept	What it means	What labeling says
Pregnancy avoidance	Don't be pregnant while taking	Use reliable contraception; discontinue before planned pregnancy
Pre-pregnancy washout	Clear drug before conception attempts	Discontinue ~2 months before planned pregnancy
Lactation avoidance	Don't breastfeed while taking	Discontinue or do not breastfeed
Fertility impairment	Drug reduces capacity to conceive	Would be in fertility section; not present for approved GLP-1 drugs

Approved GLP-1 medications carry the first three but not the fourth. Retatrutide trial protocols enforce contraception during use but do not report fertility impairment.

Contrary view: what the data cannot rule out

An intellectually honest summary acknowledges what current data cannot rule out. Several limitations apply.

First, the GLP-1 class is relatively new in widespread use. Long-term reproductive outcomes over decades have not been characterized.

Second, reproductive endpoints are not the focus of obesity trials. Subtle effects on fertility markers may not be detected in a trial designed around weight loss.

Third, retatrutide specifically has a small human safety database compared to approved drugs. Effects that emerge with broader use may not yet have been detected.

Fourth, the triple-agonist mechanism (GLP-1 + GIP + glucagon receptor) is unique. Class-effect reasoning from GLP-1-only or dual agonists may not capture glucagon-receptor-specific effects on reproductive physiology, if any exist.

The reasonable position is that no current data supports a fertility-impairment claim, but the absence of evidence is not equivalent to evidence of absence. For an investigational drug, the precautionary principle weighs more heavily than for established medications.

Decision framework

If you are concerned about future fertility:

• Approved GLP-1 medications do not carry fertility-impairment warnings in current labeling.
• For investigational drugs like retatrutide, access is limited to trials and the question is largely academic.

If you are trying to conceive now:

• Approved GLP-1 labeling recommends discontinuation 1-2 months before conception attempts in women.
• Men generally do not have explicit washout requirements in labeling, though some clinicians recommend one.

If you have obesity-related infertility:

• Weight loss often improves fertility markers. GLP-1 medications are an established weight-loss tool.
• Reproductive endocrinology consultation can frame the timing.

If you encountered an online claim that GLP-1 drugs cause infertility:

• Consider whether the claim distinguishes between pregnancy avoidance and fertility impairment. The two are often conflated.

Retatrutide status for this question

For Does Retatrutide Cause Infertility? What the Evidence Actually Supports, the starting point is regulatory status: retatrutide remains investigational as of May 2026 and is not FDA-approved. FormBlends does not sell, prescribe, dispense, or supply retatrutide; the legitimate access path is clinical-trial participation.

This page is education about the evidence and safety boundaries for does, retatrutide, cause, infertility. It is not dosing, purchasing, mixing, or preparation guidance. If you need treatment now, ask a licensed clinician about approved options such as semaglutide or tirzepatide.

FAQ

Does retatrutide cause infertility? No published evidence supports this. Direct human fertility data has not been reported.

Why is pregnancy not recommended? Animal reproductive toxicity data at maternally toxic doses drives pregnancy-avoidance labeling for the class. Pregnancy avoidance is not the same as fertility impairment.

Can it cause permanent infertility? No published evidence supports this.

What about early menopause? No mechanism identified. Ovarian reserve depletion is age-driven, not GLP-1 related in published data.

Do GLP-1 drugs improve fertility? Often, in people with obesity-related fertility problems. The effect is weight-mediated.

How long before pregnancy should I stop? For approved GLP-1 drugs, labeling suggests 1-2 months. Retatrutide is investigational; trial protocols typically exclude planned conception during participation.

What is the half-life? Approximately 6 days.

Is retatrutide FDA-approved? No. Retatrutide is investigational and not FDA-approved.

Where do infertility claims come from? Conflation of pregnancy-avoidance labeling with fertility-impairment claims, plus discussion of weight-loss-related menstrual changes.

Related guides

• Retatrutide and Male Fertility: A Closer Look at What the Evidence Actually Shows
• Switching from High-Dose Tirzepatide to Retatrutide: What the Evidence Does and Doesn't Say
• Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
• Does Retatrutide Cause Muscle Loss? Lean Mass Data and What to Do About It
• Can Retatrutide Cause Cancer? Thyroid Risk, Class Effects, and What We Don't Know
• Does Retatrutide Cause Diarrhea? The Phase 2 Numbers in Context

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). NEJM. 2023;389:514-526.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2024.
4. Zepbound (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
5. Saxenda (liraglutide) prescribing information. Novo Nordisk. Revised 2023.
6. Jensterle M et al. Semaglutide in women with PCOS. European Journal of Endocrinology. 2022;186:535-545.
7. Calderon B et al. Bariatric surgery and male hypogonadism. Obesity Surgery. 2014;24:1686-1692.
8. ACOG. Polycystic Ovary Syndrome Practice Bulletin. Obstetrics & Gynecology. 2018.
9. ASRM. Obesity and reproduction: a committee opinion. Fertility and Sterility. 2021.
10. Endocrine Society Clinical Practice Guideline. Testosterone Therapy in Men with Hypogonadism. 2018.
11. ClinicalTrials.gov. TRIUMPH Program Records. Accessed May 2026.
12. Norman RJ et al. Improving reproductive performance in overweight/obese women. Human Reproduction Update. 2004;10:267-280.
13. Wilding JPH et al. Once-Weekly Semaglutide for Obesity (STEP 1). NEJM. 2021;384:989-1002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not manufacture, prescribe, or dispense medication.

Compounded Medication Notice. Compounded preparations from 503A pharmacies are not FDA-approved or reviewed through the FDA approval process and not interchangeable with branded approved products. Retatrutide is not lawfully compoundable because it is investigational.

Results Disclaimer. Fertility outcomes are influenced by many factors. Statements about general patterns describe averages from published literature, not individual predictions.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of Novo Nordisk and Eli Lilly. Retatrutide is an investigational compound from Eli Lilly. FormBlends is not affiliated with these manufacturers.